StockStory.org on MSN
DXCM Q4 deep dive: New product launches and international strategy drive outlook
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results , with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results